Week Ending January 18, 2022

You Don’t Have to Be a Smoker to Get Lung Cancer
“SATURDAY, Jan. 15, 2022 (HealthDay News) — Think you’re safe from lung cancer because you’ve never smoked? Think again.”

Nivo-Ipi Consolidation Fails to Demonstrate Long-Term Survival Advantage Over Placebo in SCLC
“The immunotherapy combination of nivolumab and ipilimumab did not extend progression-free survival in patients with small cell lung cancer when compared with placebo.”

Gilead and Merck to trial Trodelvy-Keytruda combo for lung cancer
“The Phase III trial of Trodelvy plus Keytruda to treat metastatic NSCLC will be sponsored by Merck.”

Adjuvant Pembrolizumab Extends DFS in Stage IB-IIIA Non–Small Cell Lung Cancer
“Interim results from the phase 3 KEYNOTE-091 show promise for the use of pembrolizumab in patients with stage IB-IIIA non–small cell lung cancer treated in the adjuvant setting.”

Young Investigators awarded $200k to study innovative new ways to engage the body’s immune system to fight lung cancer
“Lung Cancer Foundation of America (LCFA) and the International Lung Cancer Foundation (ILCF) are excited to announce the winners of two new Young Investigator grants”

Progress on Lung Cancer Drives Overall Decline in U.S. Cancer Deaths
“WEDNESDAY, Jan. 12, 2022 (HealthDay News) — A new report offers hope on the lung cancer front: Patients are being diagnosed at an earlier stage in their disease and living longer due to better access to care, higher screening rates and improved treatments.”

Blood Test Helps Identify Who Will Benefit From Lung Cancer Screening
“— Biomarker panel plus risk model detects 9% more cases that should be referred for screening”

Know the Risks and Benefits of Robotic Navigational Bronchoscopy for Lung Cancer
“While robotic navigational bronchoscopy is an exciting advancement in diagnosing and staging lung cancer, the procedure does come with some risks and factors to consider, explained one expert.”

Dr. Catherine Shu Discusses a Study with Important Implications for Lung Cancer Treatment
“DocWire News spoke with Dr. Catherine Shu, a board-certified medical oncologist specializing in the treatment of thoracic cancers, specifically lung cancer, on the findings from Janssen’s CHRYSALIS-2 study, which demonstrated the efficacy of amivantamab in combination with lazertinib in the treatment of patients with non-small cell lung cancer.”